Semiconductor based aSi 1000 EPID detectors for in vivo dosimetry for VMAT treatment in prostate cancer: a novel approach to dose verification

IF 1.6 3区化学 Q3 CHEMISTRY, ANALYTICAL

Journal of Radioanalytical and Nuclear Chemistry Pub Date : 2025-09-13 DOI:10.1007/s10967-025-10383-w

Dinesh Kumar, Anirudh Pradhan, Vishnu Chauhan

引用次数: 0

Abstract

This study evaluates the feasibility of amorphous silicon (aSi 1000) electronic portal imaging device (EPID) detectors for in vivo dose verification during volumetric modulated arc therapy (VMAT) treatment in prostate cancer. EPID calibration unit (CU) signals were converted into dose using a self-developed algorithm and validated with phantom and patient data. Among 53 patients, mean dose deviation from TPS was < 1%, with 64% within 5% and 7% exceeding 10%. The method demonstrated ~ 5% uncertainty. EPID-based dosimetry offers a practical real-time verification tool, enhancing treatment accuracy and patient safety in clinical radiotherapy.

查看原文本刊更多论文

用于VMAT治疗前列腺癌的体内剂量测定的半导体as1000 EPID检测器：一种剂量验证的新方法

本研究评估了非晶硅（aSi 1000）电子门静脉成像装置（EPID）探测器在体积调制电弧治疗（VMAT）前列腺癌治疗过程中用于体内剂量验证的可行性。EPID校准单元（CU）信号使用自行开发的算法转换为剂量，并使用幻影和患者数据进行验证。53例患者中，平均剂量偏离TPS为1%，其中64%在5%以内，7%超过10%。该方法的不确定度为~ 5%。基于epid的剂量测定提供了一种实用的实时验证工具，提高了临床放疗的治疗准确性和患者安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Radioanalytical and Nuclear Chemistry 化学-分析化学

CiteScore

2.80

自引率

18.80%

发文量

504

审稿时长

2.2 months

期刊介绍： An international periodical publishing original papers, letters, review papers and short communications on nuclear chemistry. The subjects covered include: Nuclear chemistry, Radiochemistry, Radiation chemistry, Radiobiological chemistry, Environmental radiochemistry, Production and control of radioisotopes and labelled compounds, Nuclear power plant chemistry, Nuclear fuel chemistry, Radioanalytical chemistry, Radiation detection and measurement, Nuclear instrumentation and automation, etc.